Publication:
High-throughput analysis of antimalarial susceptibility data by the worldwide antimalarial resistance network (WWARN) In Vitro analysis and reporting tool

dc.contributor.authorCharles J. Woodrowen_US
dc.contributor.authorSabina Dahlströmen_US
dc.contributor.authorRichard Cookseyen_US
dc.contributor.authorJennifer A. Fleggen_US
dc.contributor.authorHervé Le Nagarden_US
dc.contributor.authorFrance Mentréen_US
dc.contributor.authorClaribel Murilloen_US
dc.contributor.authorDidier Ménarden_US
dc.contributor.authorFrançois Nostenen_US
dc.contributor.authorKanlaya Sriprawaten_US
dc.contributor.authorLise Musseten_US
dc.contributor.authorNeils B. Quashieen_US
dc.contributor.authorPharath Limen_US
dc.contributor.authorRick M. Fairhursten_US
dc.contributor.authorSam L. Nsobyaen_US
dc.contributor.authorVeronique Sinouen_US
dc.contributor.authorHarald Noedlen_US
dc.contributor.authorBruno Pradinesen_US
dc.contributor.authorJacob D. Johnsonen_US
dc.contributor.authorPhilippe J. Guerinen_US
dc.contributor.authorCarol H. Sibleyen_US
dc.contributor.authorJacques Le Brasen_US
dc.contributor.otherNuffield Department of Clinical Medicineen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherHopital Bichat-Claude-Bernard AP-HPen_US
dc.contributor.otherUniversite Paris 7- Denis Dideroten_US
dc.contributor.otherCentro Internacional de Entrenamiento e Investigaciones Medicasen_US
dc.contributor.otherInstitut Pasteur du Cambodgeen_US
dc.contributor.otherShoklo Malaria Research Uniten_US
dc.contributor.otherInstitut Pasteur de la Guyaneen_US
dc.contributor.otherUniversity of Ghanaen_US
dc.contributor.otherNational Institute of Allergy and Infectious Diseasesen_US
dc.contributor.otherNational Center for Parasitology, Entomology and Malaria Controlen_US
dc.contributor.otherMakerere Universityen_US
dc.contributor.otherAix Marseille Universiteen_US
dc.contributor.otherMedizinische Universitat Wienen_US
dc.contributor.otherInstitut de recherche biomedicale des armeesen_US
dc.contributor.otherUnite de Recherche sur les Maladies Infectieuses et Tropicales emergentesen_US
dc.contributor.otherCentre National de Référence du Paludismeen_US
dc.contributor.otherWalter Reed Projecten_US
dc.contributor.otherUniversity of Washington, Seattleen_US
dc.contributor.otherUniversite Paris Descartesen_US
dc.contributor.otherIRD Institut de Recherche pour le Developpementen_US
dc.date.accessioned2018-10-19T05:22:20Z
dc.date.available2018-10-19T05:22:20Z
dc.date.issued2013-07-01en_US
dc.description.abstractAssessment of in vitro susceptibility is a fundamental component of antimalarial surveillance studies, but wide variations in the measurement of parasite growth and the calculation of inhibitory constants make comparisons of data from different laboratories difficult. Here we describe a Web-based, high-throughput in vitro analysis and reporting tool (IVART) generating inhibitory constants for large data sets. Fourteen primary data sets examining laboratory-determined susceptibility to artemisinin derivatives and artemisinin combination therapy partner drugs were collated from 11 laboratories. Drug concentrations associated with half-maximal inhibition of growth (IC50s) were determined by a modified sigmoid Emaxmodel-fitting algorithm, allowing standardized analysis of 7,350 concentration-inhibition assays involving 1,592 isolates. Examination of concentration-inhibition data revealed evidence of apparent paradoxical growth at high concentrations of nonartemisinin drugs, supporting amendment of the method for calculating the maximal drug effect in each assay. Criteria for defining more-reliable IC50s based on estimated confidence intervals and growth ratios improved correlation coefficients for the drug pairs mefloquine-quinine and chloroquine-desethylamodiaquine in 9 of 11 and 8 of 8 data sets, respectively. Further analysis showed that maximal drug inhibition was higher for artemisinins than for other drugs, particularly in ELISA (enzyme-linked immunosorbent assay)-based assays, a finding consistent with the earlier onset of action of these drugs in the parasite life cycle. This is the first high-throughput analytical approach to apply consistent constraints and reliability criteria to large, diverse antimalarial susceptibility data sets. The data also illustrate the distinct biological properties of artemisinins and underline the need to apply more sensitive approaches to assessing in vitro susceptibility to these drugs. Copyright © 2013, American Society for Microbiology.en_US
dc.identifier.citationAntimicrobial Agents and Chemotherapy. Vol.57, No.7 (2013), 3121-3130en_US
dc.identifier.doi10.1128/AAC.02350-12en_US
dc.identifier.issn10986596en_US
dc.identifier.issn00664804en_US
dc.identifier.other2-s2.0-84879030186en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/32285
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84879030186&origin=inwarden_US
dc.subjectMedicineen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleHigh-throughput analysis of antimalarial susceptibility data by the worldwide antimalarial resistance network (WWARN) In Vitro analysis and reporting toolen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84879030186&origin=inwarden_US

Files

Collections